Optimizing Biologic Therapy in Children with Moderate-to-Severe Atopic Dermatitis: A Care Team Forum®


Provided by RMEI Medical Education, LLC  


Target Audience

Dermatology, allergy/immunology, pediatricians, and primary care clinicians

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the role of type 2 inflammation in the pathogenesis of moderate-to-severe atopic dermatitis (AD) and other atopic diseases  
  • Apply key data on available and emerging biologic therapies for the treatment of moderate-to-severe AD in children 
  • Integrate the unique roles and responsibilities of the interprofessional care team when managing common comorbidities in children with moderate-to-severe AD 


Bob Geng, MD
Voluntary Associate Clinical Professor, Allergy & Immunology
Co-Director, AAFA-sponsored Severe Asthma Program
Rady Children's Hospital
Allergy/Immunology Director, Multidisciplinary Atopic Dermatitis Program
University of California San Diego
President, San Diego Allergy Society
San Diego, CA

Lauren Loop
Eczema Educator/Lead Clinical Research Coordinator
Rady Children’s Hospital
Director, Grants and Rare Disease
Allergy and Asthma Medical Group and Research Center
Executive Director, San Diego Allergy Society
San Diego, CA

Reid Oldenburg, MD, PhD
Assistant Professor, Department of Dermatology
University of California San Diego
San Diego, CA

Katie Smiley, PA-C
Clinic Coordinator, Multidisciplinary Atopic Dermatitis Program
Rady Children’s Hospital
San Diego, CA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Bob Geng, MD, has relevant financial relationships with ADMA Biologics Inc., AstraZeneca, BPL, Chiesi USA, Inc., Galderma, Kenota Health, Leo Pharma, Novartis, Pharming, Quest (Consultant); ADMA Biologics Inc., Chiesi USA, Inc., Incyte Corporation, Sanofi, X4 Pharmaceuticals, Inc. (Grant/Research Support); AbbVie, BioCryst Pharmaceuticals, Inc., GlaxoSmithKline, Grifols, Horizon, OptiNose, Pfizer, Regeneron, Sanofi, Takeda (Speakers/Speaker’s Bureau).

Lauren Loop, has no relevant financial relationship(s) with ineligible companies to disclose.

Reid Oldenburg, MD, PhD, has relevant financial relationships with AbbVie (Research Support).

Katie Smiley, PA-C, has no relevant financial relationship(s) with ineligible companies to disclose.

Caregiver (Christy) participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement


In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation

Physician Continuing Medical Education

RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit


In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the posttest
  • MOC points will be submitted to ABIM profiles within 4 weeks of completion

Note: RMEI Medical Education, LLC will share completion information with ABIM via ACCME’s Program Activity Reporting System (PARS)

There is no fee to participate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.


Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.